Not sure how you can say they already have access to blinded data and that is useful. All that they will really be able to say is that there are no AE’s that would have potentially caused a stoppage of the trial. So they can not get a head start on the data as you are suggesting IMO but DYOR.
EU regulators reject Leqembi for Alzheimers, page-26
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $70.90M | |||
| Open | High | Low | Value | Volume |
| 2.3¢ | 2.4¢ | 2.3¢ | $44.25K | 1.881M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 2727066 | 2.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.4¢ | 526273 | 4 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| ACW (ASX) Chart |